Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia

https://doi.org/10.1016/0002-9343(86)90251-2Get rights and content

Abstract

It is often difficult to differentiate between an exacerbation of systemic lupus erythematosus (SLE) and intercurrent pre-eclampsia in a patient with SLE since the manifestations of both entities include proteinuria and hypertension. This study was undertaken to determine whether serum C3 and C4 values can help distinguish SLE activity from pre-eclampsia. In 21 nonpregnant women of child-bearing age, the mean C3 level was 124 ± 5 mg/dl and the mean C4 was 31 ± 1 mg/dl. In 24 normal women in the third trimester of pregnancy, the C3 and C4 levels were elevated (165 ± 4 mg/dl, p <0.001 versus nonpregnant control women; 37 ± 2 mg/dl, p <0.01 versus nonpregnant control women, respectively). In 17 women in the third trimester of pregnancy with documented pre-eclampsia, the mean C3 level was 162 ± 4 mg/dl, no different from that in normal pregnant women (p <0.001 versus nonpregnant control women; p = NS versus normal pregnant women), and the mean C4 was 29 ± 3 mg/dl, lower than that found in normal pregnant women (p <0.02 versus normal pregnant women). Antinuclear antibody was absent at titers of less than 1:20 in all of these pre-eclamptic patients. In contrast, pregnant women with SLE had significantly lower C3 (103 ± 13 mg/dl) and C4 (15.3 ± 3.6 mg/dl) values during the third trimester of pregnancy than either normal pregnant women (p <0.001 for C3 and C4) or women with pre-eclampsia (p <0.001 for C3 and p <0.004 for C4) during the third trimester of pregnancy. Of the eight women with SLE in whom serial complement values were determined, three had falling C3 or C4 levels, and in each, there was a flare of SLE activity either during or immediately after pregnancy. None of the five patients with a rising C3 concentration had a flare of disease activity; however, pre-eclampsia developed in one of these patients, characterized by hypertension and proteinuria. Thus, measurement of serum C3 and C4 can help differentiate between SLE activity and pre-eclampsia, since both C3 and C4 are significantly lower in women with SLE than women with pre-eclampsia, and serum C3 and C4 concentrations rise during uncomplicated or pre-eclamptic pregnancy in women with SLE.

References (30)

  • A Steinberg

    Management of systemic lupus erythematosus

  • EM Tan et al.

    The 1982 revised criteria for the classification of systemic lupus erythematosus

    Arthritis Rheum

    (1982)
  • GJ Friou

    Immunofluorescence and antibodies

    Arthritis Rheum

    (1964)
  • G Mancini et al.

    Immunochemical quantitation of antigens by single radial immunodiffusion

    Immunochem

    (1965)
  • S Honig et al.

    C-reactive protein in systemic lupus erythematosus

    Arth Rheum

    (1977)
  • Cited by (88)

    • Pregnancy in systemic lupus erythematosus

      2023, Best Practice and Research: Clinical Rheumatology
    • Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome

      2017, Best Practice and Research: Clinical Rheumatology
      Citation Excerpt :

      For example, fatigue, mild thrombocytopenia, and anaemia, commonly encountered during pregnancy, may be mistaken for evidence of heightened disease activity. Similarly, changes in complement concentrations, classic serologic markers of SLE activity, may not be reliable biomarkers during pregnancy [33]. More recently, various instruments for measuring SLE activity have been adapted to pregnancy [34].

    • A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus

      2016, Journal of Autoimmunity
      Citation Excerpt :

      This distinction is critical because the two conditions are managed in opposite ways: LN requires immunosuppression, whereas for severe PE or eclampsia delivery, even very preterm, may be indicated. A detailed evaluation of other biomarkers of SLE activity, as anti-dsDNA titre, low level of complement, active urine sediment (red cells, white cells and cellular casts) and the presence of extra-renal SLE manifestation may be helpful [65–67]. Obstetrical and neonatal complications in LN pregnancy remain greater than in general population; favourable pregnancy outcome ranges from 65 to 90%.

    • The complement system and adverse pregnancy outcomes

      2015, Molecular Immunology
      Citation Excerpt :

      Lupus flares in pregnancy are often characterized by severe hypertension and proteinuria, and distinction from severe preeclampsia is difficult. While preeclampsia is not characterized by low C3 or C4 levels as seen with lupus in pregnancy (Buyon et al., 1986), the ratio of complement split products (i.e., C3a/C3 and C4d/C4) are elevated in preeclampsia suggesting excess complement activation with relative depletion of C3 and C4 (Derzsy et al., 2010). On the other hand, both severe preeclampsia and lupus have been associated with increased terminal complement activation as measured by plasma and urine biomarkers C5a and sC5b-9 (Burwick et al., 2013; Chiu et al., 1998; Gou et al., 2013).

    • Dysregulated Complement Activation as a Common Pathway of Injury in Preeclampsia and Other Pregnancy Complications

      2010, Placenta
      Citation Excerpt :

      Indeed, complement activation products have been demonstrated in deciduas, chorionic villi and vessel walls in placentas of patients with aPL and in patients with preeclampsia [77,81,84]. Studies performed over a decade ago found evidence of complement activation in pregnant patients with SLE [75,76,85–87]. It may be difficult to identify decreased complement synthesis or increased consumption due to lupus because changes induced by gestation can either falsely normalize (if synthesis increases) or exaggerate (if synthesis does not increase) disease-related hypocomplementemia [75,76,88].

    View all citing articles on Scopus

    This research was supported by Grants AM-11949 and HL-19421 from the National Institutes of Health to Dr. Weissmann. Dr. Cronstein is a Fellow of the Arthritis Foundation.

    View full text